Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05407727 · ClinicalTrials.gov registry record
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy
A clinical trial, sponsored by Praxis Precision Medicines.
- Completed
- Registry status
- 5
- Enrollment target
NCT05407727: Completed study, sponsored by Praxis Precision Medicines.
NCT05407727 is a clinical trial that has completed, run by Praxis Precision Medicines. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05407727 has completed, sponsored by Praxis Precision Medicines.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This prospective observational study is designed to assess the individualized baseline disease burden in pediatric participants aged 1 year to 16 years, with early-onset SCN2A-DEE by characterizing and quantifying changes in clinical features over a period of up to 12 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2023-03-31 |
What the finished NCT05407727 record still lists
NCT05407727 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05407727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05407727 about?
NCT05407727 is a clinical study titled "A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy". This prospective observational study is designed to assess the individualized baseline disease burden in pediatric participants aged 1 year to 16 years, with early-onset SCN2A-DEE by characterizing and quantifying changes in clinical features over a period of up to 12 months.
What is the current status of trial NCT05407727?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2022-04-15. Estimated completion is 2023-03-31.
Who is sponsoring clinical trial NCT05407727?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI